MedPath

BRISTOL MYERS SQUIBB

🇫🇷France
Ownership
-
Established
1989-01-01
Employees
30K
Market Cap
$97.5B
Website
https://www.bms.com/

Safety Sudy of Atazanavir Boosted With Ritonavir in the Treatment of HIV Infection in Pediatric Patients

Phase 4
Completed
Conditions
HIV, Pediatric
Interventions
First Posted Date
2012-09-25
Last Posted Date
2018-04-27
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
108
Registration Number
NCT01691794
Locations
🇺🇸

Children'S Medical Center Of Dallas, Dallas, Texas, United States

🇺🇸

Phoenix Children'S Hospital, Phoenix, Arizona, United States

🇿🇦

Local Institution, Cape Town, Western CAPE, South Africa

and more 1 locations

Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma

Phase 2
Completed
Conditions
Melanoma
Interventions
First Posted Date
2012-09-07
Last Posted Date
2015-06-11
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
21
Registration Number
NCT01681212
Locations
🇯🇵

Local Institution, Chuo-shi, Yamanashi, Japan

Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC

Phase 3
Completed
Conditions
Non-Squamous Cell Non-small Cell Lung Cancer
Interventions
Biological: Nivolumab
Drug: Docetaxel
First Posted Date
2012-08-28
Last Posted Date
2023-02-08
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
582
Registration Number
NCT01673867
Locations
🇺🇸

Local Institution - 0035, Sayre, Pennsylvania, United States

🇧🇷

Local Institution - 0054, Salvador, Bahia, Brazil

🇺🇸

Local Institution - 0033, Dallas, Texas, United States

and more 84 locations

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

Phase 2
Completed
Conditions
Melanoma
Interventions
Drug: Ipilimumab
Biological: Vemurafenib
First Posted Date
2012-08-28
Last Posted Date
2018-07-24
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
70
Registration Number
NCT01673854
Locations
🇺🇸

University Hospitals Of Cleveland, Cleveland, Ohio, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Winship Cancer Institute, Atlanta, Georgia, United States

and more 11 locations

Pattern Of Use Of Belatacept In US Transplant Recipients

Completed
Conditions
Kidney Transplantation: Transplantation, Kidney
First Posted Date
2012-08-21
Last Posted Date
2018-07-13
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
5000
Registration Number
NCT01670058

Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)

Phase 3
Completed
Conditions
Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma
Interventions
Biological: Nivolumab
Drug: Everolimus
First Posted Date
2012-08-20
Last Posted Date
2022-08-09
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
821
Registration Number
NCT01668784
Locations
🇫🇷

Local Institution - 0006, Vandoeuvre-lès-Nancy, Lorraine, France

🇮🇹

Local Institution - 0102, Rozzano, Italy

🇫🇷

Local Institution - 0007, Lyon Cedex, France

and more 73 locations

Proof of Concept Study of BMS-823778 to Assess the Effects on Atherosclerosis

Phase 2
Withdrawn
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Drug: BMS-823778
Drug: Placebo matching with BMS-823778
First Posted Date
2012-08-16
Last Posted Date
2013-06-21
Lead Sponsor
Bristol-Myers Squibb
Registration Number
NCT01666704

Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib

Phase 4
Completed
Conditions
Chronic Phase Chronic Myeloid Leukemia
Interventions
First Posted Date
2012-08-09
Last Posted Date
2016-11-22
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
39
Registration Number
NCT01660906
Locations
🇺🇸

Pacific Cancer Medical Center, Anaheim, California, United States

🇺🇸

Promedica Hematology & Oncology Assoicates, Sylvania, Ohio, United States

🇰🇷

Local Institution, Seoul, Korea, Republic of

and more 3 locations

An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer

Phase 1
Completed
Conditions
Hepatocellular Carcinoma
Interventions
First Posted Date
2012-08-07
Last Posted Date
2024-11-19
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
659
Registration Number
NCT01658878
Locations
🇺🇸

Local Institution - 0002, Ann Arbor, Michigan, United States

🇺🇸

Local Institution - 0008, Los Angeles, California, United States

🇺🇸

Local Institution - 0048, Washington, District of Columbia, United States

and more 57 locations

Belatacept and Risk of Post-transplant Lymphoproliferative Disorder in US Renal Transplant Recipients

Completed
Conditions
Kidney Transplantation
Transplantation, Kidney
Interventions
Drug: Calcineurin inhibitors (CNI)
Drug: Belatacept
First Posted Date
2012-08-03
Last Posted Date
2022-07-22
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
775
Registration Number
NCT01656343
© Copyright 2025. All Rights Reserved by MedPath